About Us

Scythian Biosciences Corp. is a pre-clinical research and development company that is in the process of developing drug therapies. The first project underway is the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. In addition to this primary line of research and development, Scythian also intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for treatment of gastro-inflammatory disease.

Pipeline

Scythian’s first patent application covers a two-drug combination therapy for concussive treatment. That is, the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid. NMDA antagonists inhibit white blood cell activity within injured brain tissue, stopping cytokine release and further brain damage.

Technology

For contact sports players, repeated concussions can have devastating effects later in life. Chronic traumatic encephalopathy (CTE), a disease symptomatically similar to Alzheimer’s, as well as other forms of dementia have been linked to repeated concussive episodes for which there is no FDA approved drug regimen.